Drugs / Sulbactam-durlobactam
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07485010 | Apr 2027 → Apr 2031 expected | pulmonary non-tuberculous mycobacterial infection | The University of Queensland | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sulbactam-durlobactam | “IV sulbactam/durlobactam Greater than or equal to 130ml/min Every FOUR (4) hourly. Administered by intravenous infusion over 3 hours.” NCT07485010 ↗ |
| Route | Intravenous | “Administered by intravenous infusion over 3 hours.” NCT07485010 ↗ |